GlassScriptPhysician profile
Marissa Arin Evancho
NPI 1427647817
$2,610.85
in general payments reported to CMS, 2019-2025
24 companies · $787 in 2025
The $787 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.80 · 2022: $398 · 2023: $592 · 2024: $775 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.89 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $447.59 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $341.70 | 2021-2025 | Farxiga, Wainua, Brilinta |
| Janssen Pharmaceuticals, INC | $319.00 | 2022-2024 | Xarelto |
| Amgen INC. | $308.49 | 2022-2025 | Repatha, Repatha |
| Novo Nordisk INC | $279.12 | 2023-2025 | Ozempic, Wegovy |
| Pfizer INC. | $220.06 | 2022-2025 | |
| Esperion Therapeutics, INC. | $108.40 | 2023-2025 | Nexletol |
| Abiomed | $88.05 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $72.44 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $52.07 | 2024-2025 | Uptravi, Opsumit |
| Edwards Lifesciences Corporation | $43.56 | 2024-2025 | Pascal, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lexicon Pharmaceuticals, INC. | $39.45 | 2023-2024 | Inpefa |
| Merck Sharp & Dohme LLC | $35.31 | 2024-2025 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $34.80 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.68 | 2021-2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $28.26 | 2023 | |
| Terumo Medical Corporation | $27.42 | 2022 | |
| Kestra Medical Technology Services, INC. | $24.58 | 2025 | Assure Wcd |
| Bridgebio Pharma, INC. | $23.87 | 2025 | Attruby |
| Medtronic, INC. | $20.06 | 2022 | |
| Amarin Pharma, INC. | $17.62 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.32 | 2022 | |
| Glaxosmithkline, LLC. | $14.61 | 2025 | Shingrix |
| Altathera Pharmaceuticals LLC | $14.39 | 2024 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marissa Evancho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.